Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure

Table 1 General characteristics of the two groups

Group	Number of patients	Sex		Cause of disease		Age
		Male	Female	Chronic nephritis, nephrotic syndrome, renal tubulointerstitial disease	Others
Observation group	33	17 (51.51)	16 (48.48)	24 (72.72)	9 (27.27)	66.98 ± 6.45
Control group	32	18 (56.25)	14 (43.75)	22 (68.75)	10 (31.25)	67.13 ± 6.13
χ2/t	-	0.146		0.124		0.096
P value	-	0.701		0.724		0.923

Data are presented as mean ± SD or n (%).